CytoDyn Shares Update on PRO 140 Therapy Trial

Biotech Investing

CytoDyn enrolled 34 patients in its Phase 2b/3 trial of PRO 140 in combination with antiretroviral therapy in HIV-infected patients.

CytoDyn (OTC:CYDY) enrolled 34 patients in its Phase 2b/3 trial of PRO 140 in combination with antiretroviral therapy (ART) in HIV-infected patients.
As quoted in the press release:

Thirty-three of the enrolled patients have finished the one-week efficacy endpoint of the study and eleven patients have completed the full 25-week protocol with undetectable viral loads. Ten patients are currently in a rollover study after completing the 25-week trial. The Company is confident that it has met the enrollment criteria for the trial. The U.S. Food and Drug Administration has set a meeting on October 17 to discuss the next steps in CytoDyn’s efforts towards the analysis of primary efficacy endpoint and filing of a Biologics License Application for PRO 140.

Click here to read the full press release.

Source: globenewswire.com

biologics biologics license application endpoint enrollment food and drug administration hiv patients Biotech Investing